about
A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultscml biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure.Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature.Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsOptimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.Still embedded together binding to membranes regulates Bcl-2 protein interactions.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Regulating cell death at, on, and in membranes.Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells--Mitochondrial Outer Membrane Permeabilization and Beyond.A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.The proapoptotic protein tBid forms both superficially bound and membrane-inserted oligomers.Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic AberrationsMultiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBid.Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche.A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.Sam68 Allows Selective Targeting of Human Cancer Stem Cells.Cyclic thrombocytopenia with statistically significant neutrophil oscillations.Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSA phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemiaBim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.Mixed variant multicentric Castleman disease treated with rituximab: case reportExamining the molecular mechanism of bcl-2 family proteins at membranes by fluorescence spectroscopyAllosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of BaxUnleashing Blocked Apoptosis in Cancer Cells: New MCL1 Inhibitors Find Their GrooveIdentification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML RecurrenceHow we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registryAn MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
P50
Q34305899-135B4256-467E-410B-859C-DAA9E18D80AEQ35145688-1297C35F-7609-4DA3-A76A-5EE438E95DF1Q35155748-38EFD7D5-F8AD-4115-8167-198B835D7C61Q35178966-6FDF5018-C1A9-4C1D-8A72-512AFB213AE6Q36118340-3930CC6A-3479-409B-A4C6-783474541881Q37209768-209988CD-1EB1-48C9-91A7-25BD7C0D9F0CQ37577651-1D6BC93B-0B54-4680-99B2-43DFAA0DF886Q37773789-82EA6568-6883-464F-AA02-6CC254110AFAQ38207017-694D5741-1169-4DF9-9608-DF18C50FF8E9Q38220096-51801935-A6BB-43B8-B1C5-7EDBCA340DFCQ38394646-27C69A3A-F2EE-48A9-9393-1EE8F0EAA9C2Q38403347-5BFBA126-D6F9-4008-8A2C-3007EB994D1EQ38432040-929E783F-14C4-4B24-904F-9F6F38A17D4EQ38816384-EF789DCE-ADBD-423E-BEDE-036DC31EABB5Q38956996-2A846616-9CF4-416E-8A23-081D33291C12Q38990833-ADB3C368-380E-4297-9E01-9B0C303E5FD4Q40538336-41A3A5D7-E168-4BF6-9CD7-535A281AAEDAQ41265804-1D99960F-3FCE-4EEA-819F-96CBE2340A1AQ42060470-CE5199F6-2153-43C3-B232-F0CF8C090AF7Q42593963-3184F87B-94E2-47E5-9F69-99C3A6F55EC2Q44532454-2E41363A-F640-4857-8CCA-BABD3176CAFAQ47162210-5A5F069D-D3AE-4430-ADA8-E0041FB74A93Q47648907-37453314-2759-41F1-BB26-C697D4E4B79CQ47702710-DC2CC5C5-3D4E-470D-8006-0F0C797BC130Q48175966-452067C5-44C7-4CBA-B80B-149F006583BBQ48181095-445B0E36-2504-4752-9094-4A816B2ABE8AQ48300373-63BD6D70-F000-487B-A577-F655153A6A8BQ50925360-368E3AB3-5251-4F49-BC95-82462BAC4EADQ55486499-5E52E4A7-D90D-4B0F-8E7A-715C36C035E1Q57073363-3759F805-6F3E-4C3A-AB86-AFED43553F99Q57169390-F39F9614-094A-4DD3-9A49-2037CEF2925BQ64101953-9D0F3E4D-298A-4F14-8A5C-C83555C9A733Q64904953-C2035942-ABDF-4793-A215-B84E901BDC6AQ85157520-08A50F5C-CE71-488F-9D2F-AF8C2A24DCC5Q88174437-EDE8069A-2EE3-4CBE-9433-8B308D205397Q89451439-EBF80D71-2B9F-4956-9D5D-A0576D57B6ABQ90226525-9C706F6F-4914-4884-8B5A-95C584BD15ACQ91385888-280E2CB4-D51F-479D-9E5A-C129012E87ABQ91645647-F496D194-205E-4B62-9239-C19752276508Q91768414-D5A8F549-5079-4C99-9A1A-37F78B6434E3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
B Leber
@en
B Leber
@nl
type
label
B Leber
@en
B Leber
@nl
prefLabel
B Leber
@en
B Leber
@nl
P31
P496
0000-0001-5502-1480